Search Results - "Shimada, Yohta"

Suppression of lysosomal acid alpha‐glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer by Hamura, Ryoga, Shirai, Yoshihiro, Shimada, Yohta, Saito, Nobuhiro, Taniai, Tomohiko, Horiuchi, Takashi, Takada, Naoki, Kanegae, Yumi, Ikegami, Toru, Ohashi, Toya, Yanaga, Katsuhiko

“…Lysosomal degradation plays a crucial role in the metabolism of biological macromolecules supplied by autophagy. The regulation of the autophagy‐lysosome…”
Get full text

Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells by Taniai, Tomohiko, Shirai, Yoshihiro, Shimada, Yohta, Hamura, Ryoga, Yanagaki, Mitsuru, Takada, Naoki, Horiuchi, Takashi, Haruki, Koichiro, Furukawa, Kenei, Uwagawa, Tadashi, Tsuboi, Kazuhito, Okamoto, Yasuo, Shimada, Shu, Tanaka, Shinji, Ohashi, Toya, Ikegami, Toru

“…Although the inhibition of acid ceramidase (AC) is known to induce antitumor effects in various cancers, there are few reports in pancreatic cancer, and the…”
Get full text

Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II by Hoshina, Hiroo, Shimada, Yohta, Higuchi, Takashi, Kobayashi, Hiroshi, Ida, Hiroyuki, Ohashi, Toya

“…Small molecules called pharmacological chaperones have been shown to improve the stability, intracellular localization, and function of mutated enzymes in…”
Get full text

Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy by Miwa, Saori, Watabe, Ayako M., Shimada, Yohta, Higuchi, Takashi, Kobayashi, Hiroshi, Fukuda, Takahiro, Kato, Fusao, Ida, Hiroyuki, Ohashi, Toya

“…Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disease (LSD) caused by a deficiency of the iduronate-2-sulfatase (IDS) that catabolizes…”
Get full text

Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II by Wakabayashi, Taichi, Shimada, Yohta, Akiyama, Kazumasa, Higuchi, Takashi, Fukuda, Takahiro, Kobayashi, Hiroshi, Eto, Yoshikatsu, Ida, Hiroyuki, Ohashi, Toya

“…Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), which leads to the…”
Get more information

Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation by Shirai, Yoshihiro, MD, PhD, Uwagawa, Tadashi, MD, PhD, Shiba, Hiroaki, MD, PhD, Shimada, Yohta, PhD, Horiuchi, Takashi, MD, Saito, Nobuhiro, MD, Furukawa, Kenei, MD, PhD, Ohashi, Toya, MD, PhD, Yanaga, Katsuhiko, MD, PhD

“…Background Thrombomodulin, an anticoagulant that inhibits thrombin-induced growth factor promotion, also has an anti-inflammatory effect. Furthermore,…”
Get full text

Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis by Tsunogai, Toshiki, Ohashi, Toya, Shimada, Yohta, Higuchi, Takashi, Kimura, Ayaka, Watabe, Ayako M., Kato, Fusao, Ida, Hiroyuki, Kobayashi, Hiroshi

“…GM1-gangliosidosis is a progressive neurodegenerative glycosphingolipidosis resulting from a GLB1 gene mutation causing a deficiency of the lysosomal enzyme…”
Get full text

Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition by Fujiwara, Yuki, Furukawa, Kenei, Haruki, Koichiro, Shimada, Yohta, Iida, Tomonori, Shiba, Hiroaki, Uwagawa, Tadashi, Ohashi, Toya, Yanaga, Katsuhiko

“…Background Constitutive activation of nuclear factor kappa-B (NF-κB) contributes to the aggressive behavior of pancreatic cancer. Over-expression of downstream…”
Get full text

A novel preclinical model of mucopolysaccharidosis type II for developing human hematopoietic stem cell gene therapy by Shimada, Yohta, Ishii, Natsumi, Higuchi, Takashi, Goto, Motohito, Ohashi, Toya, Kobayashi, Hiroshi

Get full text

Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis by Tsunogai, Toshiki, Ohashi, Toya, Shimada, Yohta, Higuchi, Takashi, Kimura, Ayaka, Watabe, Ayako M., Kato, Fusao, Ida, Hiroyuki, Kobayashi, Hiroshi

Get full text

Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp) by Kawagoe, Shiho, Higuchi, Takashi, Otaka, Manami, Shimada, Yohta, Kobayashi, Hiroshi, Ida, Hiroyuki, Ohashi, Toya, Okano, Hirotaka J., Nakanishi, Mahito, Eto, Yoshikatsu

“…We generated iPS cells from human dermal fibroblasts (HDFs) of Fabry disease using a Sendai virus (SeVdp) vector; this method has been established by Nakanishi…”
Get full text

Ex Vivo Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation by Wada, Miho, Shimada, Yohta, Iizuka, Sayoko, Ishii, Natsumi, Hiraki, Hiromi, Tachibana, Toshiaki, Maeda, Kazuhiro, Saito, Mitsuru, Arakawa, Shoutaro, Ishimoto, Takuya, Nakano, Takayoshi, Ida, Hiroyuki, Ohashi, Toya, Kobayashi, Hiroshi

“…Mucopolysaccharidosis type II is a disease caused by organ accumulation of glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated…”
Get full text

Autophagy contributes to lysosomal storage disorders by Shimada, Yohta, Klionsky, Daniel J

“…Degradation in the lysosome/vacuole is not the final step of autophagy. In particular, for starvation-induced autophagy it is necessary to release the…”
Get full text

TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle by Sato, Yohei, Kobayashi, Hiroshi, Higuchi, Takashi, Shimada, Yohta, Ida, Hiroyuki, Ohashi, Toya

“…Pompe disease (PD) is a lysosomal disorder caused by acid α-glucosidase (GAA) deficiency. Progressive muscular weakness is the major symptom of PD, and enzyme…”
Get full text

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells by Sugano, Hiroshi, Shirai, Yoshihiro, Horiuchi, Takashi, Saito, Nobuhiro, Shimada, Yohta, Eto, Ken, Uwagawa, Tadashi, Ohashi, Toya, Yanaga, Katsuhiko

“…Neoadjuvant chemoradiotherapy followed by radical surgery is the standard treatment for patients with locally advanced low rectal cancer. However, several…”
Get full text

A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice by Shimada, Yohta, Wakabayashi, Taichi, Akiyama, Kazumasa, Hoshina, Hiroo, Higuchi, Takashi, Kobayashi, Hiroshi, Eto, Yoshikatsu, Ida, Hiroyuki, Ohashi, Toya

“…Mucopolysaccharidosis type II (MPS II) is an X-linked lysosomal storage disorder arising from deficiency of iduronate-2-sulfatase (IDS), which results in…”
Get full text

Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient by Sato, Yohei, Kobayashi, Hiroshi, Higuchi, Takashi, Shimada, Yohta, Era, Takumi, Kimura, Shigemi, Eto, Yoshikatsu, Ida, Hiroyuki, Ohashi, Toya

“…Pompe disease is an autosomal recessive inherited metabolic disease caused by deficiency of acid α-glucosidase (GAA). Glycogen accumulation is seen in the…”
Get full text

Correction: Adipose Tissue-Derived Mesenchymal Stem Cells in Long-Term Dialysis Patients Display Downregulation of PCAF Expression and Poor Angiogenesis Activation by Yamanaka, Shuichiro, Yokote, Shinya, Yamada, Akifumi, Katsuoka, Yuichi, Izuhara, Luna, Shimada, Yohta, Omura, Nobuo, Okano, Hirotaka James, Ohki, Takao, Yokoo, Takashi

“…[This corrects the article DOI: 10.1371/journal.pone.0102311.]…”
Get full text

Comparison of multipotency and molecular profile of MSCs between CKD and healthy rats by Yamada, Akifumi, Yokoo, Takashi, Yokote, Shinya, Yamanaka, Shuichiro, Izuhara, Luna, Katsuoka, Yuichi, Shimada, Yohta, Shukuya, Akinori, Okano, Hirotaka James, Ohashi, Toya, Ida, Hiroyuki

“…We previously showed that mesenchymal stem cells (MSCs) can differentiate into a functional miniature kidney, suggesting that MSCs may be a cell source for…”
Get full text

Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice by Akiyama, Kazumasa, Shimada, Yohta, Higuchi, Takashi, Ohtsu, Makoto, Nakauchi, Hiromitsu, Kobayashi, Hiroshi, Fukuda, Takahiro, Ida, Hiroyuki, Eto, Yoshikatsu, Crawford, Brett E., Brown, Jillian R., Ohashi, Toya

“…Before the availability of an enzyme replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II), patients were treated by bone marrow transplantation…”
Get full text